Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03031418 · ClinicalTrials.gov registry record
Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)
A clinical trial of Cancer Of Prostate, sponsored by Exosome Diagnostics.
- Completed
- Registry status
- 532
- Enrollment target
- 18
- Study locations
NCT03031418 is a study of Cancer Of Prostate that has completed, run by Exosome Diagnostics. The registered enrollment target is 532 participants, below the 1,863-participant average among 7 other Cancer Of Prostate trials with a reported enrollment target (71% lower). The trial reports 18 study locations across 11 states.
The verdict
NCT03031418, a study of Cancer Of Prostate, has completed, sponsored by Exosome Diagnostics.
- COMPLETED
- Registry status
- 532 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this research study is investigate a new and validated urine test which predicts the likelihood of high grade prostate cancer on an initial prostate biopsy The current protocol has two objectives; one is to further assess and evaluate the performance of the urine test in men already scheduled for initial prostate needle biopsy (cohort (group) 1) and two, to evaluate how the results of the urine test influences the decision process for determining whether to perform a prostate biopsy (cohort (group) 2).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST ExoDx Prostate Intelliscore
Study Locations (18)
New York
- Manhattan Medical Research - New York
- NYU Urology Associates - New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University Medical Center - New York
New Jersey
- Premier Urology Group - Edison
- Urologic Research and Consulting LLC - Englewood
- Delaware Valley Urology - Voorhees Township
Florida
- 21st Century Oncology - Fort Myers
- Mount Sinai Medical Center of Florida - Miami
Maryland
- Johns Hopkins University - Baltimore
- Walter Reed National Military Medical CPDR - Bethesda
Georgia
- Southeastern Urology Associates - Macon
Michigan
- Comprehensive Urology - Royal Oak
Montana
- Five Valley Urology - Missoula
North Carolina
- Associated Urologists of North Carolina - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 532 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2018-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03031418
The ClinicalTrials.gov registry entry for NCT03031418 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 532 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,863-participant average among 7 other Cancer Of Prostate trials with a reported enrollment target (71% lower). The listed sponsor is Exosome Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer Of Prostate appearing as the primary indexed condition, and to 1 intervention - of which ExoDx Prostate Intelliscore is the first listed.
NCT03031418 reports 18 study locations spanning 11 distinct geographic areas - top geographies include New York, New Jersey, Florida.
Frequently Asked Questions
What is clinical trial NCT03031418 about?
NCT03031418 is a clinical study titled "Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)". The purpose of this research study is investigate a new and validated urine test which predicts the likelihood of high grade prostate cancer on an initial prostate biopsy The current protocol has two objectives; one is to further assess and evaluate the performance of the urine test in men already s...
What is the current status of trial NCT03031418?
This trial is currently completed. The enrollment target is 532 participants. The study started on 2016-09-01. Estimated completion is 2018-09-01.
What conditions does trial NCT03031418 study?
This clinical trial studies the following conditions: Cancer Of Prostate.
What interventions are being tested in trial NCT03031418?
The interventions under investigation include: ExoDx Prostate Intelliscore (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03031418?
This trial is sponsored by Exosome Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03031418 being conducted?
This trial has 18 study locations across Florida, Georgia, Maryland, Michigan, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer Of Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Prostate Cancer
RECRUITING
-
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
RECRUITING · Phase 1
-
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
RECRUITING
-
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
RECRUITING · Phase 2
-
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
RECRUITING · Phase 1
-
Onco-primary Care Networking to Support TEAM-based Care
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.